IBD patients may see relief of inflammation with antidepressants

Inflammatory bowel disease patients who take antidepressants may also get relief from their inflammation, according to a study published in Inflammatory Bowel Diseases. “Apart from improving mood, it is observed that the anti-inflammatory properties of antidepressants may influence the inflammatory response directly,” the authors wrote. “Other research suggests a bidirectional relationship between IBD activity and

IBD can contribute to sexual dysfunction

According to a study in Inflammatory Bowel Diseases, patients with inflammatory bowel disease often struggle with body image and sexuality and this could lead to sexual dysfunction. Men with IBD who were younger than 50 and women younger than 40 had a significantly increased risk, the study said. “Inflammatory bowel disease could have a major

Crohn’s & Colitis Congress 2019 in Las Vegas

Assessing which care guideline to follow can be a challenge for many providers who care for patients with inflammatory bowel diseases (IBD). To help IBD health care professionals navigate these complexities, the 2019 Crohn’s & Colitis Congress® will focus its opening session on How to Make Sense of Care Guidelines. See Dr. David Rubin from the University

No microscopic colitis risk with gluten

An association between celiac disease and microscopic colitis has long been recognized. A study published in The American Journal of Gastroenterology explored the possibility of non-celiac sensitivity to gluten. The results suggested eating a diet that contains gluten did not increase the risk for microscopic colitis in women who do not already have celiac disease. See

IBD and Unconventional Remedies

An estimated 30-50%, and possible 60%, of patients with inflammatory bowel disease (IBD) turn to complementary and alternative medicines (CAM’s) to ease symptoms and exert more control over their treatment. Very few studies have evaluated CAM’s, and many of the studies were small, poorly designed, and uncontrolled. Predictors of CAM use include dissatisfaction with conventional therapies,

Entyvio safe and effective for UC in real-world study

An analysis of data from the VICTORY consortium through the University of California at San Diego, as published in The American Journal of Gastroenterology, found vedolizumab effective in ulcerative colitis. Cumulative rates of endoscopic remission and clinical remission were the main effectiveness outcomes of the review. Researchers analyzed secondary outcomes measures of cumulative rates of

Study Supports Safety of Infliximab in Pregnancy

An analysis of data from the TREAT Registry found that babies born to women who continued to treat their Crohn’s disease with infliximab during pregnancy had outcomes similar to those who did not take the drug. “The majority of both maternal pregnancies and partner outcomes resulted in live births of healthy infants across exposure groups”

Biosimilars in Europe lead to lower prices

Dr. Jonathan Kay of the University of Massachusetts Medical School told the 2018 Interdisciplinary Autoimmune Summit that biosimilar competition in Europe has reduced drug costs, made biosimilars more available and increased market share for some bio-originators. The European Union has approved 41 biosimilar drugs while the FDA has approved nine. Biosimilars in Europe lead to